BusinessIndustries
Trending

Global Angioedema Treatment Market-Outlook, Opportunity, Projects, Application and Company Analysis 2019-2025

The latest report on Angioedema Treatment Market by Infinium Global Research gives complete coverage of the angioedema treatment market by drugs type (C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor), route of administration (oral, and injections), end-user (hospitals, clinics, and research organizations) in terms of key trends, market size, forecast. In addition, the study covers deep dive into key product and applications trends in the regional markets of angioedema treatment such as North America, Europe, Asia-Pacific and Latin America over the short run and long run.

Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/6076

Angioedema Treatment Market: Industry Insights

Angioedema is a common condition caused due to allergies and shows abrupt swelling under the skin surface. There are four different types of angioedema as allergic angioedema, drug-induced angioedema, Idiopathic angioedema, and hereditary angioedema. Angioedema is mediated by several mechanisms, including histamine and bradykinin or another mechanism. Diagnosis of the specific type of angioedema is crucial for proper treatment.

Angioedema Treatment Market: Drivers and Restraints

The rapidly increasing number of allergies and allergy conditions such as angioedema drives the growth of the angioedema treatment market. Hereditary angioedema occurs in approximately 1out of 30,000 to 80,000 individuals and affects less than 8,000 individuals in the United States (USA), 15,000 in Europe, and 200,000 worldwide. Furthermore, the growing approvals of novel drugs for the treatment of angioedema favor the growth of the angioedema treatment market. However, lack of awareness among people about angioedema restraints the growth of the market. Moreover, growing clinical trials for the development of drugs for hereditary angioedema creates beneficial opportunities for the growth of the market.

Request a Discount on Standard Prices of this Premium Report @ https://www.infiniumglobalresearch.com/reports/request-discount/6076

Angioedema Treatment Market: Segmentation

The drugs segment includes C1 esterase inhibitors such as Cinryze, Berinert, Ruconest and Haegarda, Selective bradykinin B2 receptor antagonist, Kallikrein inhibitor and several others. The route of administration of these drugs includes injections and oral. The end users are further classified as hospitals, clinics, and research organizations. Among them, the hospital segment dominates the global angiodema treatment market as diverse treatment options for angioedema are available in hospitals. Furthermore, hospitals also provide medication in the correct dosage and appropriate form and make physicians aware of any possible adverse reactions.

Angioedema Treatment Market: Regional Insights

North America dominates the global market for angioedema treatment owing to the high prevalence of allergic conditions and more awareness about such medical conditions. Furthermore, high spending capacity on healthcare and the presence of several major manufacturers drives the growth of the angioedema treatment market in the North America region. While increasing allergies in adults and children have triggered the growth rate of angioedema treatment in Europe.

Read Detailed Index of full Research Study at https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-angioedema-treatment-market

Angioedema Treatment Market: Competitive Landscape

The key market players in the angioedema treatment market include AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AstraZeneca Plc, Valeant Pharmaceuticals International, Sanofi S.A and Merck & Co., Inc. The companies in the angioedema treatment market are focusing on the development of new products to gain a competitive advantage in the market. For instance, in 2017, the U.S. Food and Drug Administration approved Haegarda, a C1 Esterase Inhibitor (Human) for subcutaneous administration indicated for the preventing hereditary angioedema (HAE) in adult and adolescent patients.

Reasons to Buy this Report:

  • Comprehensive analysis of global as well as regional markets of the angioedema treatment.
  • Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.
  • Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.  
  • Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Tags

Related Articles

Close